The number on the wire is $77 million. That is what a Series B costs when you take a first-in-class antibody-drug conjugate into its first patient. InduPro closed the round and dosed that patient on the same day, August 12.
The $77M Series B pools Merck, Sanofi and Eli Lilly strategic funds with The Column Group and Vida Ventures, an unusual big-pharma cluster for a Phase 1 company.
Its proximity-labeling platform was invented inside Merck's own exploratory science center; Merck backs the company and runs a separate bispecific-discovery collaboration valued at up to roughly $950 million.
The context is squamous cancers. Many of the advances that reshaped other solid tumors skipped them: no driver mutation to hit, no approved ADC target on the cell surface in most cases. InduPro's argument is that the biology of the tumor surface, mapped as a spatial map rather than a list of markers, opens a way in.
Seventy-seven million dollars, one syringe
InduPro is a Seattle and Cambridge, Massachusetts biotech that translates the spatial layout of membrane proteins into drug targets. It builds bispecific antibodies, ADCs and T-cell engagers for oncology and autoimmune disease. The Series B closed and the first patient was dosed on the same day, and the sequencing is deliberate: the money funds the trial, and the trial is what the money is for.
The syndicate reads like a shortlist of strategic desire. The Column Group led. Existing backers Vida Ventures, MRL Ventures Fund, the therapeutics arm of Merck & Co., Emerson Collective and Euclidean Capital came back in. New money came from Solasta Ventures, Sanofi and Eli Lilly. Terms beyond the headline were not disclosed.
InduPro Series B, closed same day first patient dosed
Round led by The Column Group; Merck, Sanofi and Eli Lilly strategic funds participate. Proceeds fund the IDP-001 Phase 1 program and preclinical pipeline. · Business Wire / AllSci, 2026
A bispecific that earns its specificity
Conventional ADCs attach one antibody to a cytotoxic payload and depend on the target being abundant on the tumor. EGFR is a proven oncogene, but EGFR-targeting ADCs have a history of a different kind. The receptor is also on normal tissue, and the balance between tumor effect and on-target toxicity has limited the class. That is the gap IDP-001 is built for.
IDP-001 binds EGFR and TAPA-E1, a tumor-associated proximity antigen the company found by mapping which proteins sit physically adjacent to EGFR on the surface of tumor cells, not which ones are merely co-expressed. The drug's specificity claim rests on the pair appearing together only on tumors. The company calls the discovery engine MInt, a membrane interactomics platform built on proximity-labeling proteomics.
Preclinical data add shape. In vitro, IDP-001 showed activity across cancer lines with different target-expression levels, including osimertinib-resistant EGFR-mutant non-small cell lung cancer (NSCLC), and minimal activity against normal cells carrying both targets. It uses a monomethyl auristatin E (MMAE) payload at a low drug-to-antibody ratio. Xenograft studies showed antitumor effect.
Why not just another EGFR-targeting ADC?
Confirmation criteria: a Phase 1 dose range without dose-limiting on-target toxicity and signs of antitumor activity.
"The targets for our bispecific ADC were selected based not only on their shared biology across squamous tumors, but also on their proximity on the surface of cancer cells, a spatial relationship not found in normal tissue."— Amanda J. Redig, Chief Medical Officer, InduPro
Strategic pharma interest on multiple fronts
A company that maps the tumor surface as a neighborhood is not a random project. InduPro’s proximity-labeling technology was invented at the Merck Exploratory Science Center, and co-founders Rob Oslund and Niyi Fadeyi came out of it. MRL Ventures Fund, Merck’s therapeutics venture arm, is in the Series B. In parallel, InduPro runs a separate collaboration with Eli Lilly, valued at up to roughly $950 million in milestones, to discover bispecific and multispecific oncology therapeutics.
| Dimension | Conventional ADC | Proximity-based bispecific ADC |
|---|---|---|
| Target logic | Single antigen, chosen by expression level | Co-target pair, chosen by physical adjacency on the tumor surface |
| Tolerability | On-target toxicity often limits the dose | Dual binding designed to widen the therapeutic window |
| Evidence base | Validated targets, multiple approved drugs | First-in-class claim, Phase 1 readout still pending |
Industry trackers count roughly 211 bispecific ADCs in development, per a survey from June 2026, with only a handful in Phase 3 and not a single one approved anywhere. The modality is young enough that platform economics, not sales, carry the valuation conversation. That makes the series of milestones here unusually legible: dose escalation in 2027, then early efficacy, then the real question of whether the spatial hypothesis survives contact with a bigger sample.
What happens to ADC deal flow a year from now?
Probability: 60%. Three pharma strategic funds already wrote checks into one round, and the constraint this modality addresses, EGFR-class on-target toxicity, is well documented.
✅ Arguments for
Confirmation criteria: a second Phase 1 proximity-based bispecific ADC start in the next 12 months, or a licensing deal built on a proximity-mapping platform.
❌ Arguments against
Disconfirmation criteria: a complete or partial response rate near zero at the first efficacy look, or a prominent developer exiting the modality.
Development scenarios
🟢 Optimistic scenario (35%)
Implications: proximity mapping becomes a named feature of ADC diligence, not a footnote.
🟡 Base-case scenario (45%)
Implications: the company stays a private platform bet; the strategic syndicate remains the primary audience for its equity.
🔴 Pessimistic scenario (20%)
Implications: a re-rating of spatial biology as a drug-discovery idea, not a drug-delivery one.
These numbers do not come from a model. They are a description of how investor attention behaves when a novel modality meets a single-arm readout: big when the biology fits the story, impatient when it does not. As we wrote in August, Ratio Therapeutics raised $70 million for actinium-225, a radioactive payload with a two-centimetre range. InduPro's $77 million is a similar bet on a different targeting logic: radioactivity in one case, spatial biology in the other. Neither molecule has read out yet, which is why the right posture is to watch both rather than judge them.
Any disclosed dose-escalation data from NCT07602842 in 2027, particularly the dose-limiting toxicity profile.
Movement in the Merck collaboration: added programs or realized milestones under the ~$950M ceiling.
Whether TAPA discovery extends beyond oncology into the company's stated autoimmune arena.
The pricing of a future financing within 18 months, which acts as the market's verdict on the modality.
